Dr. Clay Siegall leads Seattle Genetics to innovation and success

The success of Seattle Genetics is highly attributed to the work of Dr. Clay Siegall. He has been an authority in the company and has a high passion for working on cancer therapies. He is one of the co-founders of the company that started in 1998. He serves today as the President, Chairman of Board and Chief Executive Officer of Seattle Genetics. His work in the company has seen him guide the company to paths of great success. He steered to company to the finding of ADCs, Antibody Drug Conjugate that are extremely important in the treatment of cancer.

Seattle genetics today has licenses under several companies that serve the ADC technology. Examples of these companies include Pfzer, Genentech and other companies. Such partnerships have enabled the company generate up to $300 million in terms of funding. Dr. Siegall has played the biggest role in these funding. He has partnered with multiple companies that Seattle Genetics found instrumental for its growth. As one of the directors, he was behind the company’s first public offering in 2001. From that time on, he has been able to amass more than $675 million funding for the company.

Clay Siegall has made a major impact in cancer research and better treatment products for cancer. Seattle Genetics today has the promise of developing 12 new cancer drugs. The aim is to treat various cancer cells and make the lives of those suffering from cancer better. Seattle Genetics had only 100 employees a few years ago. It boasts of 800 employees today.

The company expects to have an additional employees of 100 this year. The employees are going to work on research and development of new products that should aid cancer treatment. To make the company house additional workers, Seattle Genetics is set to expand its space at the Canyon Creek Park. It plans to rent other floors and occupy close to 350,000 square feet of office space. Seattle Genetics is further set to open new offices in Switzerland. It plans to have an additional 20 workers that will work hand in hand with the European Medicine Agency.